Equillium (EQ) Accumulated Depreciation (2017 - 2025)
Equillium (EQ) posted quarterly Accumulated Depreciation of $562000.0 for Q4 2025, up 12.63% year-over-year from $499000.0 in Q4 2024, and up 12.63% quarter-over-quarter from $499000.0 in Q4 2024.
Equillium (EQ) Accumulated Depreciation (2017 - 2025) Analysis & Trends
Equillium (EQ) has reported Accumulated Depreciation for 9 consecutive years, with $562000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 12.63% year-over-year to $562000.0; the TTM figure through Dec 2025 stood at $562000.0 (up 12.63% YoY), while the FY2025 annual figure was $562000.0, up 12.63% from the prior year.
- Accumulated Depreciation climbed to $562000.0 in Q4 2025 per EQ's latest filing, from $499000.0 in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $562000.0 in Q4 2025 and bottomed at $147000.0 in Q4 2021.
- Historically, Accumulated Depreciation has averaged $364200.0 across 5 years, with a median of $364000.0 in 2023.
- Annual changes were most pronounced in 2021 — Accumulated Depreciation jumped 98.65% — and 2025, when it increased 12.63%.
- Equillium's Accumulated Depreciation stood at $147000.0 in 2021, then surged by 69.39% to $249000.0 in 2022, then soared by 46.18% to $364000.0 in 2023, then surged by 37.09% to $499000.0 in 2024, then advanced by 12.63% to $562000.0 in 2025.
- Business Quant data shows EQ's Accumulated Depreciation at $562000.0 in Q4 2025, $499000.0 in Q4 2024, and $364000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 562,000.00 |
| Dec 31, 2024 | 499,000.00 |
| Dec 31, 2023 | 364,000.00 |
| Dec 31, 2022 | 249,000.00 |
| Dec 31, 2021 | 147,000.00 |
| Dec 31, 2020 | 74,000.00 |
| Dec 31, 2019 | 29,000.00 |
| Dec 31, 2018 | 6,000.00 |
| Dec 31, 2017 | 122.00 |